adplus-dvertising
Connect with us

Business

COVID-19: B.C. hit with 'overwhelming' response to book AstraZeneca vaccines – Vancouver Sun

Published

 on


Starting today people aged 55 to 65 living in the Lower Mainland can book a vaccine but people can expect delays and waitlists to book a jab.

Article content

Starting today people aged 55 to 65 living in the Lower Mainland can book an AstraZeneca/COVISHIELD vaccine, but so far the rollout has not gone smoothly.

Frustrated folks in the region faced busy phone signals at pharmacies, jammed websites, waitlists, and at least one pharmacy chain saying it was all booked up.

On Tuesday night, a day before the bookings opened for this category, London Drugs announced on Twitter that due to an “overwhelming response,” all vaccine appointments had been booked at the three London Drugs pharmacies selected by the B.C. government to offer the vaccine.

The company asked people not to call the pharmacies so they can prepare for the “fully booked” appointments.

Those who felt confused or daunted by the process took to social media to complain about the booking system. Some were upset about London Drugs booking on Tuesday ahead of the Wednesday start, while others despaired over not being able to get a booking because the pharmacy had already run out of AstraZeneca.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

There are dozens of pharmacies around the region offering the jab. The B.C. Pharmacy Association website has a list of pharmacies offering the vaccine, which will be updated regularly in the coming weeks.

However, callers to several pharmacies on the list were met with a busy signal Wednesday morning, indicating a demand for the vaccine.

The 2019 population data for those aged 55 to 65 in the Lower Mainland show there are 275,457 people in that age category in the Fraser Health Authority and 176,431 in Vancouver Coastal.

Those trying for an appointment on the North Shore faced difficulties. For instance, Davies Prescription Pharmacy, which is one of two North Shore pharmacies on the vaccination list, said they were out of a very limited supply of AstraZeneca vaccine on Wednesday morning, while the other one on the list is a London Drugs, which is booked. There is no pharmacy listed for West Vancouver.

The Costco Pharmacy in Abbotsford said they haven’t received any AstraZeneca yet and directed people to add their name to a waitlist at costco.ca.  Rexall pharmacies also has a waitlist.

The Ministry of Health has been contacted to address the situation.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Interim leader of the Official Opposition Shirley Bond and MLA Renee Merrifield, the B.C. Liberal critic for health, released a joint statement Wednesday, saying the NDP’s “constant bungling” is creating confusion and concern over vaccinations.

The government announced Tuesday that those in the age 55 to 65 category could start booking vaccines, but many pharmacies were overwhelmed or didn’t know they were on the vaccination list, they said.

“For weeks we have consistently been asking John Horgan to include community pharmacies as part of the rollout and to have a clearly laid out plan. That didn’t happen and British Columbians deserve better. Yesterday was just another example of incompetence from a government that cannot manage to deliver on critical programs like the vaccination rollout, they said.

“Now the 55 to 65 age cohort in the Lower Mainland is left wondering what happened after feeling a sense of hope about the possibility of being vaccinated. We can certainly understand how people are feeling frustration and anger about the latest problems with the vaccination rollout.”

Bond and Merrifield said there needs to be a provincial booking system.

London Drugs’ announcement caused many social media users to express frustration about how people could book on Tuesday when they were told by government that bookings opened on Wednesday.

The company has been contacted for a response but has not yet returned messages.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

The province decided to bump up its age-based immunization plan for AstraZeneca shots after concerns about rare blood clots prompted the National Advisory Committee on Immunization to pause the use of the vaccine for anyone under 55.

Provincial health officer Dr. Bonnie Henry says in a news release that the vaccine remains highly effective and its benefits for those over 55 far outweigh the risks of COVID-19 infection.

More than 99,000 B.C. residents have been diagnosed with COVID-19 since the start of the pandemic and infections have surged across the province in recent weeks, with 840 new cases reported Tuesday.

“As soon as the news was public all of our Lower Mainland British Columbia stores became inundated with customers wanting to book appointments,” London Drugs said on Twitter.

London Drugs said its three designated vaccination sites in Metro Vancouver have received limited allocations of the AstraZeneca vaccine.

“As soon as more supply becomes available, we will open up our online booking similarly to what we would do with routine flu vaccinations. We are ready to vaccinate as many people as possible and expect more information on increased allotment will be coming in the days ahead.”

Those going to get a vaccine will be required to bring their Personal Health Number, located on your CareCard or driver’s license.

The AstraZeneca/COVISHIELD vaccine is currently not available in pharmacies in the Northern, Interior, and Vancouver Island health authorities at this time.

-with files from The Canadian Press and Nathan Griffiths

ticrawford@postmedia.com


Get the latest COVID-19 news delivered to your inbox weeknights at 7 p.m. by subscribing to our newsletter here.


  1. A health worker prepares a dose of the AstraZeneca vaccine in Madrid on March 24, 2021.

    COVID-19: Dr. Henry explains future of parallel AstraZeneca track

  2. The provincial health officer, Dr. Bonnie Henry.

    COVID-19: Health Ministry mum on call to change vaccination priorities in B.C.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending